Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective

Published:2013-10 Issue:10 Volume:107 Page:1531-1537
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Paggiaro Pierluigi,Patel Shishir,Nicolini Gabriele,Pradelli Lorenzo,Zaniolo Orietta,Papi Alberto

Funder

Chiesi Farmaceutici Spa, Parma, Italy

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference35 articles.

1. European experiences with health care cost containment;AARP European Leadership Study,2006

2. Use of generics – a critical cost containment measure for all healthcare professionals in Europe;Godman;Pharmaceuticals,2010

3. The Portuguese generic medicines market: a policy analysis;Simoens;Pharm Pract,2009

4. Developing competitive and sustainable polish generic medicines market;Simoens;Croat Med J,2008

5. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France;Sermet;Appl Health Econ Health Policy,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review;Multidisciplinary Respiratory Medicine;2021-08-02

2. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK;Respiratory Medicine;2020-09

3. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions;Value in Health;2019-09

4. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force;Clinical and Translational Allergy;2019-03-27

5. Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review;Journal of Medical Economics;2019-02-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3